Clinical Trial Update: Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CO-1.01 as second-line therapy for gemcitabine-refractory metastatic pancreatic adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• CO-1.01

Snippet

Sponsor: Clovis Oncology, Inc. | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 2 | Status: COMPLETED